Clinical Trial Update: Phase II Study of NPC-14 (Arbekacin Sulfate) to Explore Safety, Tolerability, and Efficacy in Duchenne Muscular Dystrophy [Phase 2]

View source ↗

Summary

Phase II clinical trial update for NPC-14 (Arbekacin Sulfate) assessing safety, tolerability, and efficacy in Duchenne muscular dystrophy, sponsored by Kobe Uni…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• NPC-14 (Arbekacin Sulfate) (Arbekacin sulfate)

Snippet

Sponsor: Kobe University | Conditions: Muscular Dystrophy, Duchenne | Phase 2 | Status: UNKNOWN